Fluoxetine
Small molecule targets CYP2C19, CYP2D6, CYP3A4, IL6, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | SARAFEM | — | 1996-11-21 – 2014-10-10 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | PROZAC | — | 2002-07-29 – 2009-03-13 | fda.gov ↗ |
| Approved | US (FDA) | SARAFEM | — | 1987-12-29 | fda.gov ↗ |
Trials 156 · started per year
Also used as a comparator or background therapy in 127 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05789186 Comparator | May → Sep 2023 | depressive disorder | Chen Qian | Unknown | No outcome recorded |
| Phase 0 | NCT03228732 Comparator | Dec 2017 → Sep 2026 expected | type 1 diabetes mellitus | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 0 | NCT01672255 Comparator | Oct 2012 → May 2025 | type 1 diabetes mellitus | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01347541 Background | Jan → Nov 2011 | post-traumatic stress disorder | University of Washington | Terminated | No outcome recorded |
| Phase 1 | NCT00732290 Comparator | Feb → May 2009 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07239011 Comparator | Nov 2025 → Nov 2026 expected | depressive disorder | Tanta University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05030623 Background | Aug 2021 → Dec 2024 | major depressive disorder | Sadat City University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00612807 Background | Jul 2006 → Jun 2010 | major depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT05792540 Comparator | Jun 2023 → Nov 2024 | depressive disorder | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT04899687 Background | Jan 2022 → Apr 2027 expected | body dysmorphic disorder, hypochondriasis, obsessive-compulsive disorder, somatization disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT05431413 Comparator | Jan 2020 → Dec 2025 | depressive disorder | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02929667 Comparator | Feb 2017 → Mar 2019 | epilepsy | Rup Kamal Sainju | Completed | No outcome recorded |
| Phase 2 | NCT04272476 Comparator | Jan 2014 → Dec 2019 | major depressive disorder | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01254305 Comparator | Apr 2011 → Jul 2012 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00797966 Background | May 2009 → Jun 2010 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00758966 Comparator | Sep → Dec 2008 | obsessive-compulsive disorder | Orexigen Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00149643 Comparator | Sep 2004 → Aug 2009 | major depressive disorder, substance abuse | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00497562 Background | May 2004 → Nov 2005 | fibromyalgia, pituitary deficiency | Centro Medico Teknon | Completed | No outcome recorded |
| Phase 2 | NCT03051451 Comparator | ? → May 2018 | — | Laboratorios Silanes S.A. de C.V. | Suspended | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04780152 Background | Oct 2021 → Aug 2022 | major depressive disorder | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Unknown | No outcome recorded |
| Phase 2/3 | NCT01269788 Comparator | Aug 2010 → Aug 2011 | gastroesophageal reflux disease | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT06860958 Comparator | Mar 2025 → Mar 2027 expected | major depressive disorder | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT04760275 Comparator | Feb 2021 → Feb 2025 overdue | anxiety disorder | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04598230 Comparator | Feb 2021 → Aug 2025 overdue | generalized anxiety disorder, separation anxiety disorder, social phobia | Ann & Robert H Lurie Children's Hospital of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04727424 Comparator | Jan 2021 → Jun 2024 | COVID-19 | Cardresearch | Unknown | No outcome recorded |
| Phase 3 | NCT03538691 Background | Jul 2018 → Jul 2022 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03569475 Comparator | Jul 2018 → Mar 2021 | major depressive disorder | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT02709655 Comparator | May 2016 → Jan 2022 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02709746 Comparator | May 2016 → Jul 2019 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02562053 Comparator | Oct 2015 → Sep 2017 | premenstrual tension | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02624102 Background | Sep 2015 → Dec 2017 | major depressive disorder | Hemanny, Curt, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT02488538 Comparator | Jul 2015 → Jul 2017 | premenstrual tension | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02431806 Comparator | Jun 2015 → Aug 2019 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT02427334 Comparator | Apr 2015 → Dec 2021 | premenstrual tension | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02372799 Comparator | Feb 2015 → Sep 2018 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT02683213 Comparator | Oct 2014 → Jun 2020 | stroke disorder | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT01838681 Background | Jun 2013 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01687478 Background | Sep 2012 → Nov 2015 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01360866 Background | Oct 2011 → Apr 2017 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02569970 Comparator | Nov → Dec 2010 | brain hypoxia - ischemia, epilepsy | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT00958568 Comparator | Aug 2009 → Mar 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00849693 Comparator | Mar 2009 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00849901 Comparator | Mar 2009 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00578669 Comparator | Apr 2008 → Jul 2013 | major depressive disorder, nicotine dependence | Butler Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00351910 Background | May 2006 → Apr 2007 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00074815 Background | Sep 2003 → Nov 2009 | obsessive-compulsive disorder | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00118404 Comparator | Mar 2000 → Jul 2008 | depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 435 trials | ||||||
| Phase 4 | NCT07478796 Comparator | Apr 2025 → Nov 2027 expected | major depressive disorder | Poznan University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT04597190 Comparator | Jun 2020 → Aug 2024 | post-traumatic stress disorder | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT04377308 Comparator | May 2020 → Apr 2021 | COVID-19, cytokine release syndrome | University of Toledo Health Science Campus | Completed | No outcome recorded |
| Phase 4 | NCT05148169 Background | Jan 2020 → Dec 2022 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT04876521 Comparator | Oct 2019 → Jun 2021 | schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT03779789 Comparator | Feb 2019 → Feb 2023 | major depressive disorder | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 4 | NCT02238977 Comparator | Mar 2016 → Mar 2018 | end stage renal failure, major depressive disorder | University of Arkansas | Terminated | No outcome recorded |
| Phase 4 | NCT02389712 Comparator | Mar 2015 → May 2018 | bipolar disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT02357849 Comparator | Jul 2014 → Apr 2022 | — | Northwell Health | Terminated | No outcome recorded |
| Phase 4 | NCT02022709 Comparator | Jan 2014 → Nov 2017 | obsessive-compulsive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT01903447 Comparator | Dec 2013 → Feb 2018 | anxiety | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT01824433 Comparator | Mar 2013 → Mar 2017 | major depressive disorder | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01833897 Background | Mar 2013 → Jul 2014 | bipolar disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01699490 Background | Aug 2012 → Jul 2015 | major depressive disorder | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01764867 Comparator | Jun 2012 → Oct 2014 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT01460212 Comparator | Dec 2011 → Dec 2014 | major depressive disorder | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01357967 Comparator | May 2011 → Dec 2012 | major depressive disorder | Inje University | Unknown | No outcome recorded |
| Phase 4 | NCT02178696 Background | Jan 2011 → Oct 2015 | depressive disorder | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01185977 Comparator | Apr 2010 → Oct 2011 | major depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT00834834 Comparator | Mar 2009 → Aug 2015 | borderline personality disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00557427 Comparator | Jan 2009 → Nov 2010 | depressive disorder | Rafa Laboratories | Terminated | No outcome recorded |
| Phase 4 | NCT00666757 Comparator | May 2008 → Feb 2009 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00466609 Comparator | May 2007 → Mar 2010 | obsessive-compulsive disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01075529 Comparator | Mar 2007 → Feb 2010 | major depressive disorder | Kaohsiung Kai-Suan Psychiatric Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00449007 Comparator | Feb 2006 → Dec 2010 | alcohol-related disorders, major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00680602 Comparator | Jan 2006 → Sep 2008 | obsessive-compulsive disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00247624 Background | Oct 2005 → Oct 2008 | depressive disorder, sleep disorder, initiating and maintaining sleep | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00188942 Comparator | Feb 2005 → Jun 2009 | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT00768820 Background | May 2001 → Aug 2027 expected | Williams syndrome, fragile X syndrome, velocardiofacial syndrome | The Chaim Sheba Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT00061113 Comparator | Feb 2001 → Aug 2006 | alcohol-related disorders, cannabis dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 4 | NCT00006204 Background | Mar 2000 → Jan 2006 | alcohol dependence, depressive disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 4 | NCT00626340 Comparator | Jul 1999 → Jul 2008 | major depressive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01360190 Comparator | Aug 1994 → Aug 1996 | major depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00000373 Comparator | Sep 1992 → Jan 2003 | obsessive-compulsive disorder | University of Florida | Completed | No outcome recorded |
| Phase not applicable41 trials | ||||||
| — | NCT07424781 Comparator | Oct 2025 → Dec 2026 expected | major depressive disorder | University of Oxford | Recruiting | No outcome recorded |
| — | NCT07048938 Background | Jul → Dec 2025 overdue | depressive disorder | Shanghai Mental Health Center | Not yet recruiting | No outcome recorded |
| — | NCT07521358 Background | Jul → Aug 2025 | major depressive disorder | Hasanuddin University | Completed | No outcome recorded |
| — | NCT06942494 Comparator | Apr 2025 → Aug 2027 expected | obsessive-compulsive disorder | Shanghai Mental Health Center | Recruiting | No outcome recorded |
| — | NCT07025590 Comparator | Apr 2025 → Dec 2026 expected | cardiovascular disorder, mixed anxiety and depressive disorder | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| — | NCT07417046 Comparator | Dec 2024 → Mar 2026 overdue | amblyopia | Minia University | Recruiting | No outcome recorded |
| — | NCT06659094 Background | Aug 2023 → Aug 2025 | obsessive-compulsive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| — | NCT06358014 Background | May 2023 → Dec 2024 | depressive disorder | Xiao Wang | Unknown | No outcome recorded |
| — | NCT06185361 Comparator | Dec 2022 → Mar 2024 | enuresis, nocturnal, 1 | Fayoum University Hospital | Unknown | No outcome recorded |
| — | NCT05832619 Background | Nov 2022 → Dec 2025 | major depressive disorder | Xiaomei Shao | Unknown | No outcome recorded |
| — | NCT05720637 Background | Nov 2022 → Jan 2024 | major depressive disorder | Xiaomei Shao | Completed | No outcome recorded |
| — | NCT05528224 Background | Sep 2022 → Aug 2023 | obsessive-compulsive disorder | Shanghai Mental Health Center | Terminated | No outcome recorded |
| — | NCT05375851 Background | May 2022 → Aug 2023 | generalized anxiety disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| — | NCT05605002 Background | Jan 2022 → Dec 2025 | major depressive disorder | Xiaomei Shao | Unknown | No outcome recorded |
| — | NCT05588102 Background | May 2021 → May 2023 | cognitive disorder | Capital Medical University | Completed | No outcome recorded |
| — | NCT05346445 Comparator | Jan → Nov 2021 | — | Hospital Regional 1o de Octubre | Completed | No outcome recorded |
| — | NCT03072264 Comparator | Oct 2016 → Dec 2018 | generalized anxiety disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| — | NCT03558256 Background | May 2016 → Dec 2018 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT02472613 Comparator | May 2016 → Dec 2019 | — | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT02601677 Comparator | Nov 2015 → Nov 2018 | obsessive-compulsive disorder | Tang-Du Hospital | Unknown | No outcome recorded |
| — | NCT02655354 Background | Oct 2015 → Nov 2019 | alcohol-related disorders, brain injury, cognitive impairment with or without cerebellar ataxia, depressive disorder +1 | University of Washington | Completed | No outcome recorded |
| — | NCT02188225 Comparator | Jul 2014 → Feb 2019 | — | Gonabad University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT02063425 Comparator | Feb 2014 → Aug 2015 | cerebral infarction | Centre Hospitalier St Anne | Terminated | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT01740726 Comparator | Jan 2013 → Mar 2014 | major depressive disorder | Emory University | Terminated | No outcome recorded |
| — | NCT01479920 Comparator | Jun 2012 → May 2015 | major depressive disorder | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT02300051 Background | Feb 2011 → Apr 2015 | sexual disorder | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT01831440 Background | Jan 2011 → Jan 2014 | depressive disorder | Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT01148316 Comparator | Aug 2010 → Jun 2013 | obsessive-compulsive disorder | Roseli Shavitt | Completed | No outcome recorded |
| — | NCT01174394 Background | May 2010 → Feb 2013 | depressive disorder, stroke disorder | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT01136213 Comparator | Apr 2010 → Mar 2016 | multiple system atrophy | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT00986310 Comparator | Aug 2009 → Feb 2012 | focal epilepsy, respiratory underresponsiveness to hypoxia and hypercapnia | University of California, Davis | Completed | No outcome recorded |
| — | NCT00944996 Comparator | Jun 2009 → Jun 2010 | major depressive disorder | Tirat Carmel Mental Health Center | Completed | No outcome recorded |
| — | NCT01022632 Comparator | Mar 2009 → Jan 2010 | major depressive disorder | Government Medical College, Bhavnagar | Completed | No outcome recorded |
| — | NCT00158301 Background | Sep 2004 → Nov 2007 | depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00909155 Comparator | Jul 2002 → Dec 2009 | major depressive disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00965562 Comparator | Sep 2000 → Jun 2010 | premenstrual tension | Donaghue Medical Research Foundation | Completed | No outcome recorded |
| — | NCT00714779 Comparator | Jan 2000 → Dec 2004 | major depressive disorder | University of Turku | Completed | No outcome recorded |
| — | NCT00227981 Background | Mar 1995 → Mar 2001 | depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-06-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Symbyax® in the United States tevapharm.com ↗ |
| 2008-05-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Generic Sarafem® Pulvules® tevapharm.com ↗ |
| 2002-01-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval for Fluoxetine 10, 20 & 40 mg Capsules tevapharm.com ↗ |
| 2001-08-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Fluoxetine Oral Solution tevapharm.com ↗ |
| 2001-06-03 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval for Fluoxetine 10mg tevapharm.com ↗ |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 289 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluoxetine | “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗276“In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs, i.e., sertraline, fluoxetine and fluvoxamine)and tricyclic drugs(i.e., clomipramine)...” NCT06942494 ↗ “Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440 ↗ “Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of...” NCT03558256 ↗ “The investigator will initially offer treatment with fluoxetine, starting at 10mg once daily and increasing to 20mg once daily after one week if tolerated, a protocol...” NCT05002309 ↗ “Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline;...” NCT00270959 ↗ “Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline,...” NCT01347541 ↗ “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage,...” NCT01357967 ↗ “The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for...” NCT05148169 ↗ “Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of...” NCT03321526 ↗ “approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram” NCT05528224 ↗ “We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss.” NCT04437485 ↗ “SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.” NCT05832619 ↗ “quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk” NCT01796132 ↗ “This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs.” NCT06358014 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil.” NCT05375851 ↗ “alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg” NCT02178696 ↗ “Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary.” NCT04777006 ↗ “SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.” NCT05605002 ↗ “SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.” NCT05720637 ↗ “These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine.” NCT06659094 ↗ “In this study, we examined antidepressant (fluoxetine) medication adherence in children and adolescents with major depressive disorder (MDD).” PMID 20973714 ↗ Oct 2010 “Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.” NCT02624102 ↗ “Fluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression.” NCT06153004 ↗ “SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)” NCT00612807 ↗ “medication treatment will be a selective serotonin reuptake inhibitor (either fluoxetine, sertraline or escitalopram).” NCT04598230 ↗ “selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine)” NCT03993535 ↗ “serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day)” NCT02300051 ↗ “Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label” NCT01838681 ↗ “a choice of 3 selective serotonin reuptake inhibitors (SSRIs; ie, sertraline, fluoxetine, or paroxetine)” PMID 41091477 ↗ Dec 2025 “sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg” NCT01903447 ↗ “Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression.” NCT01833897 ↗ “usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents” NCT02431845 ↗ “SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline” NCT01237275 ↗ “SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline” NCT00817375 ↗ “combination therapy with the drugs amitriptyline and fluoxetine (AM+FL)” NCT00000428 ↗ “Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline” NCT03222570 ↗ “paroxetine, fluoxetine, sertraline, escitalopram, citalopram” NCT00944996 ↗ “Fluoxetine (according to response, and tolerance) 1-40mg” NCT01000402 ↗ “Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule” NCT05030623 ↗ “fluoxetine (20 mg, increased to 30 to 40 mg)” NCT00118430 ↗ “They include fluoxetine (Prozac)” NCT01460212 ↗ “-Fluoxetine 20-40 mg/d. N06AB03” NCT01305707 ↗ “fluoxetine (Prozac and others)” NCT01944657 ↗ “fluoxetine (Prozac®) capsules” NCT03538691 ↗ “Fluoxetine (Prozac) 10-60;” NCT00074815 ↗ “Fluoxetine (Prozac)” NCT00797966 ↗ “Fluoxetine, Prozac” NCT01916824 ↗ “fluoxetine_Prozac” NCT01352572 ↗ “fluoxetine_Prozac” NCT01352559 ↗ “fluoxetine_Prozac” NCT00817011 ↗ “fluoxetine_Prozac” NCT01228357 ↗ “Fluoxetine” NCT02359513 ↗ “Fluoxetine” NCT02359513 ↗ “fluoxetine” NCT00157547 ↗ “fluoxetine” NCT01488266 ↗ |
| Known as | Adofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Felicium | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Flouxetine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417046 ↗ |
| Known as | Fluctin | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluneurin | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluox-puren | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluoxeren | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | fluoxetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00768820 ↗ |
| Known as | Fluoxetin ratiopharm | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluoxetina | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluoxetine (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | fluoxetine (Prozac) | “fluoxetine (Prozac)” NCT01460212 ↗1“Fluoxetine, Prozac” NCT01916824 ↗ |
| Known as | Fluoxetine EG | “Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day” NCT00732290 ↗ |
| Known as | Fluoxetine HCl | “Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)” NCT00913588 ↗ |
| Known as | Fluoxetine Hydrochloride | “The Treatment for Adolescents With Depression Study evaluates the effectiveness of fluoxetine hydrochloride therapy, cognitive behavior therapy (CBT), and their combination in...” PMID 17909125 ↗ Oct 20078“The positive control drug was fluoxetine hydrochloride capsule with a dose of 40mg / day.” NCT05127369 ↗ “On this basis, the intervention was combined with fluoxetine hydrochloride treatment” NCT07048938 ↗ “Mylan's fluoxetine hydrochloride 40 mg capsules to Dista's Prozac 40 mg pulvules” NCT00649636 ↗ “Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules)” NCT00913588 ↗ “Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)” NCT00913718 ↗ “Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)” NCT00947076 ↗ |
| Known as | Fluoxetine Hydrochloride (generic name) | “Fluoxetine Hydrochloride (generic name)” NCT01247285 ↗1“Fluoxetine Hydrochloride (generic name)” NCT01247272 ↗ |
| Known as | Fluoxetine Hydrochloride (HCl) | “Intervention A Fluoxetine Hydrochloride (HCl)” NCT05422612 ↗ |
| Known as | Fluoxetine hydrochloride component of symbyax | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluoxétine Arrow | “Fluoxétine (Fluoxétine Arrow® 40 mg ) / Budésonide (Budecort® 2*400 mcg)” NCT04920838 ↗ |
| Known as | Flusol | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluval | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Fluxet | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | FLX | “Subjects who enroll in this project will receive 1 week of single-blind placebo lead-in, followed by 8 weeks of double-blind randomized treatment either with fluoxetine (FLX),...” NCT01185977 ↗4“For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on...” NCT01479920 ↗ “expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)” NCT01963832 ↗ “along with initiation of open-label fluoxetine (FLX).” PMID 22334811 ↗ Feb 2012 “treatment with fluoxetine (FLX).” PMID 33321509 ↗ Dec 2020 |
| Known as | Fontex | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Foxetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Lovan | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | LY110140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01569126 ↗ |
| Known as | NSC-283480 | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | NSC-758685 | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Olena | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Oxactin | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Prozac | “Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440 ↗27“This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®), lithium, the combination of these two medications, and placebo in treating and preventing...” NCT00044616 ↗ “This study will evaluate whether fluoxetine (Prozac), used together with traditional psychotherapy, can reduce aggression in people who are physically violent towards their...” NCT00011765 ↗ “This study will compare the medications fluoxetine (Prozac®) and divalproex (Depakote®) for the treatment of aggressive behavior in individuals with Intermittent Explosive...” NCT00078754 ↗ “in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft).” NCT00284791 ↗ “Prozac (medically known as fluoxetine) influences decision-making in healthy young people in four key areas that are known to be affected by depression” NCT07456501 ↗ “This phase I trial tests whether fluoxetine (prozac) works to modify the tumor immune cells before surgery in patients with colorectal cancer.” NCT06225011 ↗ “Fluoxetine (otherwise known as Prozac) has been used for many years to treat depression.” NCT02683213 ↗ “the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®, Sarafem®)” NCT00678574 ↗ “Mylan's fluoxetine hydrochloride 40 mg capsules to Dista's Prozac 40 mg pulvules” NCT00649636 ↗ “Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules)” NCT00913588 ↗ “Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)” NCT00947076 ↗ “Group 2 will receive fluoxetine (Prozac® Lilly, UK) 20mg” NCT02427334 ↗ “Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)” NCT00913718 ↗ “fluoxetine (also known as Prozac) or calcium” PMID 35978446 ↗ Aug 2022 “fluoxetine (Prozac), compared to placebo” NCT00005015 ↗ “fluoxetine (commonly known as Prozac)” NCT04570449 ↗ “Fluoxetine is also known as Prozac.” NCT00006286 ↗ “fluoxetine (Prozac and others)” NCT01944657 ↗ “fluoxetine (Prozac®) capsules” NCT03538691 ↗ “Fluoxetine (Liquid Prozac)” NCT00108316 ↗ “Fluoxetine (Prozac) 10-60;” NCT00074815 ↗ “Fluoxetine (Prozac)” NCT00797966 ↗ “fluoxetine (Prozac)” NCT00027378 ↗ “Fluoxetine (prozac)” NCT00787111 ↗ “fluoxetine (Prozac)” NCT00006204 ↗ “fluoxetine_Prozac” NCT00817011 ↗ |
| Known as | Prozac 60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Prozac weekly | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Prozep | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Prozit | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Ranflutin | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Reconcile | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Sarafem | “the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®, Sarafem®)” NCT00678574 ↗ |
| Known as | Selfemra | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Known as | Symbyax | ChEMBL registry synonym — accepted as the source's own label CHEMBL41 ↗ |
| Action | Inhibit | “the potent and selective 5-HT reuptake inhibitor fluoxetine (FX)” NCT00000373 ↗1“Serotonin transporter inhibitor” CHEMBL41 ↗ |
| Modality | Small molecule | “a selective serotonin reuptake inhibitor (SSRI)” PMID 15315995 ↗ Aug 2004 |
| Route | Oral | “Amitriptyline 25 mg po plus Fluoxitine 20 mg po” NCT00000428 ↗ |
| Target | CYP2C19 | “fluoxetine is predicted to be a moderate inhibitor of CYP2D6, but a strong inhibitor of CYP2C19 and CYP3A4.” NCT01361217 ↗ |
| Target | CYP2D6 | “fluoxetine is predicted to be a moderate inhibitor of CYP2D6, but a strong inhibitor of CYP2C19 and CYP3A4.” NCT01361217 ↗ |
| Target | CYP3A4 | “fluoxetine is predicted to be a moderate inhibitor of CYP2D6, but a strong inhibitor of CYP2C19 and CYP3A4.” NCT01361217 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL41 ↗ |